Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

/PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and...

Related Keywords

United States ,Canada ,Ottawa ,Ontario , ,Tetra Bio Pharma Inc ,European Commission ,Committee For Orphan Medicinal Products ,European Union ,European Medicines Agency ,Health Canada ,Regulation Services Provider ,Orphan Medicinal Products ,Orphan Drug Designation ,Complex Regional Pain Syndrome ,Guy Chamberland ,Chief Executive Officer ,Chief Regulatory Officer ,Tetra Bio Pharma ,Scientific Advice ,Regional Pain Syndrome ,Biotechnology ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Otc ,Mallcap ,Cannabis ,Clinical Trials Amp Medical Discoveries ,